SEC Form 4 · accession 0001209191-17-048420
Clearside Biomedical, Inc. · CLSD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
George M Lasezkay
Director
Period of report
Aug 8, 2017
Accepted (ET)
Aug 10, 2017 · 4:20 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001539029
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $7.96 | Aug 8, 2017 | A | 22,500 | A | — | Aug 7, 2027 | Common Stock | 22,500 | 22,500 | D |
Explanation of responses
- F1This option will vest and become exercisable in 36 equal monthly installments through August 8, 2020, subject to the reporting person's continuous service as of such vesting dates.